Navigation Links
Aldea Pharmaceuticals Closes $24 Million Series B Financing
Date:8/24/2014

REDWOOD CITY, Calif., Aug. 25, 2014 /PRNewswire/ -- Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, today announced that it has closed a $24 million Series B equity financing. The financing included new investors RusnanoMedInvest (RMI) and WuXi PharmaTech Corporate Ventures. All previous investors including Canaan Partners and Correlation Ventures also participated in the round.

The financing will be used to advance Aldea's lead drug candidate, AD-6626, into clinical trials, including evaluating proof-of-concept for the treatment of subjects with acute alcohol intoxication and funding subsequent Phase 2 trials of intravenous (IV) AD-6626 in an emergency room (ER) setting. In addition, Aldea is studying oral AD-6626 for the treatment of subjects with the rare genetic disease Fanconi anemia, and anticipates the financing will support a Phase 1/2 proof-of-biology study in that indication.

Every year, millions of Americans are admitted to the ER as a result of clinically significant acute alcohol intoxication, and an estimated 10 to 15 percent of ER visits are associated with alcohol consumption. Acute alcohol toxicity can be life-threatening and can lead to ER crowding, delays in critical treatment for trauma patients and intensive use of hospital resources. Since there is no antidote treatment available for alcohol toxicity, patients with acute alcohol intoxication must wait for the alcohol to be metabolized from their systems before they can be discharged from the ER.

"The use of AD-6626 in the ER setting has the potential to stabilize patients suffering from acute alcohol toxicity and more rapidly improve the signs and symptoms of intoxication than waiting for alcohol metabolism, thereby simplifying patient care. This could facilitate treatment in individuals suffering from co-morbidities such as trauma, as well as benefiting the system as a whole," noted William Yelle, chief executive officer of Aldea. "We also have the opportunity to apply our scientific approach in the treatment of patients with Fanconi anemia, a rare genetic disease characterized by chromosomal instability, bone marrow failure and an increased risk of cancer. The funds we have secured with this financing should allow us to generate proof-of-concept data in both of these indications."

About Aldea Pharmaceuticals
Aldea Pharmaceuticals is focused on developing small molecule modulators of the aldehyde dehydrogenase enzyme superfamily. The scientific approach was discovered by Stanford University researchers and exclusively licensed to Aldea. Aldea is pursuing treatment of clinically significant acute alcohol toxicity, Fanconi anemia and other diseases and conditions associated with toxic aldehydes.


'/>"/>
SOURCE Aldea Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... LabStyle Innovations Corp . ( NASDAQ: DRIO ... that the Company,s Chief Financial Officer, Zvi Ben-David ... 1-2 in New York, NY and ... Los Angeles, CA. During his ... including the U.S. FDA Clearance and commercial launch of the ...
(Date:5/27/2016)... Kitov Pharmaceuticals ... late-stage drug development, today announced the completion of ... batches required for registration of KIT-302 with the ... Kitov,s announcement in December 2015, that ... primary efficacy endpoint. "We are fortunate ...
(Date:5/26/2016)... -- According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - ... valued at US$ 5.89 Bn in 2014 and is anticipated ... 2023 to reach US$ 7.99 Bn in 2023. ... free drug delivery devices and the market is estimated based ...
Breaking Medicine Technology:
(Date:5/27/2016)... SC (PRWEB) , ... May 27, 2016 , ... ... a line of classic American timber frame barn kits, which can be found on ... are inspired by historic American barn plans, and they highlight the craftsmanship of timber ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst ... third time to shed lights on the variety of topics detailing why we appreciate ... Appreciation” tackles why this career has gone from being in a major recession to ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought ... industry, from leading advocates, associations and industry leaders such as Bioness. , ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses ... human interest stories, courtesy of leaders in the nursing and health care industry. ... from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett ...
(Date:5/27/2016)... ... ... With a team of certified experts, Validation Center is ... GMP accreditation, Validation Center is also a registered authority of the international system ... Validation Center is ISO17025 accredited and only offers its clients the latest technology, ...
Breaking Medicine News(10 mins):